Blue CHiP (Medicare and commercial) restates that home ultraviolet phototherapy (including PUVA and other home UV modalities) for dermatologic conditions is not covered, characterizing home use as a convenience rather than medically necessary. The policy notes FDA 510(k) clearance for a handheld UVB device but finds overall evidence insufficient to demonstrate home therapy is as safe or effective as office-based phototherapy. Key clinical concerns include lack of periodic dermatologist skin examinations, potential to miss early skin cancer, and limited comparative studies validating home PUVA or other home UV treatments. A single open-label trial showing comparable efficacy for home oral PUVA in hand eczema is acknowledged but deemed insufficient to change the noncoverage determination.
Revision: Restated Noncoverage of Home Phototherapy
Summary of changes in this revision
This revision restates the insurer's position on home phototherapy for dermatologic conditions, clarifying that phototherapy delivered in the home is considered not covered for both Medicare and commercial products under Blue CHiP. The document emphasizes the rationale that home-based ultraviolet light treatments, including PUVA and other home ultraviolet modalities, lack sufficient evidence of safety and effectiveness compared with office-based treatment.
The policy text also retains background references to regulatory clearance of a home UVB device (the Levia personal targeted phototherapy device) and to clinical literature (including an open-label randomized trial of oral PUVA for chronic hand eczema). However, the explicit coverage determination is unchanged in asserting that home phototherapy is considered a convenience for the member and therefore not covered.
Coverage Statement: Home Ultraviolet Phototherapy Not Covered
Coverage determination for home phototherapy under Blue CHiP
The policy explicitly states that "Phototherapy in the home for the treatment of dermatological conditions is not covered" for both Blue CHiP Medicare and commercial products. The insurer cites a lack of evidence that home-based PUVA or other home ultraviolet light treatments are as safe or effective as office-based phototherapy, and characterizes home use as a convenience for the member rather than a medically necessary service.
This coverage statement applies broadly to home ultraviolet phototherapy devices used to treat skin diseases such as psoriasis and eczema and does not specify covered indications for any particular home device.
Clinical Evidence and Safety Rationale Referenced
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.